Skip to content

This site uses cookies. By continuing to browse the site you are agreeing to our policy on the use of cookies.Continue

Pradaxa 150 mg hard capsules

Certain risk materials on this website are intended for use by healthcare professionals only.

By proceeding you are confirming that you are a healthcare professional.

You can leave feedback on specific Risk Minimisation Materials or make general observations about how they are displayed on the eMC by leaving comments in the box below.

Please note that we are unable to respond to medical queries.

Pradaxa 150 mg hard capsules


Please enter your email address below

Tick here if you wish to recieve a response to your feedback

Risk Materials
VIEW

Educational Risk Minimisation Materials to help reduce the risk associated with using this medicine.

Pradaxa (dabigatran etexilate) Patient Alert Card

Every patient prescribed Pradaxa will receive a Patient Alert Card in the medication pack. As the card contains important information the patient should be instructed to carry the patient alert card at all times and present it when seeing a health care professional. The patient should be counselled about the need for compliance and signs of bleeding and when to seek medical attention.

Pradaxa (dabigatran etexilate) Prescriber Guide for stroke prevention in non-valvular atrial fibrillation (NVAF) and for the treatment and secondary prevention of deep vein thrombosis (DVT) and pulmonary embolism (PE)

This risk minimisation material provides recommendations for the use of Pradaxa in NVAF and DVT/PE in order to minimise the risk of bleeding. Please ensure that you are familiar with this material as it contains important safety information. In particular it is aimed at increasing awareness about the potential risk of bleeding during treatment with Pradaxa and providing guidance on how to manage that risk.

For hard copies please contact our medical information department at 01344 424600 or email: medinfo@bra.boehringer-ingelheim.com

For Healthcare professionals
CLOSE THIS PANEL
View Patient Information Leaflet

The Patient Information Leaflet (PIL) is the leaflet included in the pack with a medicine. It is written for patients and gives information about taking or using a medicine.

This PIL is in PDF format and so you must have a PDF reader installed on your device to read it.

Company Information

Boehringer Ingelheim Limited

http://www.boehringer-ingelheim.co.uk

Address : Ellesfield Avenue, Bracknell, Berkshire, RG12 8YS

Telephone : +44 (0)1344 424 600

Fax : +44 (0)1344 741 298

Medical Information Direct Line : +44 (0)1344 742579 - Pradaxa enquiries

Medical Information e-mail :

More information about this medicine

Legal categories

  • POM

Active ingredients/generics

  • dabigatran etexilate mesilate

Summaries of Product Characteristics (SPCs):

© 2017 Datapharm Communications Ltd